Analyst Viewpoint
Evolution of clinical practice guidelines in the treatment of human growth hormone deficiency is a key factor that is augmenting the human growth hormone market size. Advancements in recombinant human growth hormone treatments are also driving market progress. Furthermore, global rise in awareness about human growth hormone deficiency and increase in accessibility to treatments are fostering market expansion. Governments and health organizations worldwide are conducting awareness campaigns to promote early diagnosis of the condition.
Leading companies operating in the global landscape are investing in research and development activities to create growth hormones that carry fewer side effects. They are also following the latest human growth hormone market trends and focusing on introducing effective therapies for the management of human growth hormone disorders to increase their industry share.
Human growth hormone (HGH) is responsible for development and regeneration of tissues as well as cell reproduction. It is a kind of a peptide hormone that regulates cell formation, growth stimulation, and cell regeneration in the body. HGH plays an important role in human body development.
The prevalence of growth hormone deficiency is increasing steadily across the globe. Growth hormone deficiency (GHD) is a medical condition marked by insufficient pituitary gland production of growth hormone. It affects both children and adults, and results in a variety of physical and mental difficulties.
GHD has an impact on every aspect of a person's health, from stunted growth and delayed puberty to poorer bone density, fatigue, and a lower quality of life in adults. Increase in incidence of human growth disorders has raised awareness about the significance of therapy among the worldwide population. Thus, the human growth hormone market forecast appears positive in the near future.
Clinical practice guidelines are a useful resource for practicing endocrinologists for identification, diagnosis, and treatment of patients with growth hormone deficiency. These guidelines offer assessment, screening, diagnostic testing, and therapy suggestions for adults with varied causes of GHD.
Since the first complete list of U.S. Food and Drug Administration (FDA) indications in 2003, definitions and guidelines have developed, with the most recent iteration supplied by the International Classification of Pediatric Endocrine Diagnoses (ICPED).
The recommendations emphasize the importance of testing patients with a reasonable clinical suspicion of GHD using various GH-stimulation tests to accurately diagnose GHD. They also recommend caution when interpreting serum GH and insulin-like growth factor-1 (IGF-1) levels, as these assays are used to support treatment choices.
Guidelines take a conservative approach to treating GHD patients, advocating only practices with sufficient supporting data and that minimize possible dangers to patients. Some prominent diagnostic criteria, testing, and therapy suggestions include testing for genetic problems, radiographic examination, biochemical assessment of GHD utilizing particular assays, sex steroid priming, and other GH axis tests.
Recombinant human growth hormone is a protein that is engineered to be almost identical to the natural type of human growth hormone. Applications of this human growth hormone include acceleration of tissue growth, height, as well as protein, carbohydrate, lipid, and mineral metabolism.
Benefits of HGH for muscle growth are also well-documented. Until the mid-1980s, human cadaver tissue was the only source of HGH. Its usage was forbidden when the link between pituitary-derived HGH and Creutzfeldt-Jakob disease was established.
Recombinant DNA technology has enabled safe and abundant generation of rhGH in diverse heterologous systems without the risk of human pathogen transmission, thus obviating the need for pituitary-derived preparation. Protein expression in host cells, such as E. coli, has become possible due to advances in recombinant DNA technology.
Several recent studies have confirmed the safety of long-term rhGH replacement therapy in people with GHD. Furthermore, even after more than 20 years of rhGH replacement aimed at normalizing blood IGF-1 levels in people with GHD, there is no convincing evidence that the risk of cancer, secondary neoplasms (SN), or hypothalamic-pituitary tumor recurrence is enhanced.
In order to accommodate for inter-individual variability in GH sensitivity, rhGH therapy regimens currently include dose-titration techniques aimed toward serum IGF-1 normalization, which take into account age, gender, body mass index (BMI), and a variety of other baseline factors.
Individualized, stepwise dosage modifications based on serum IGF-1 levels have resulted in enhanced therapeutic effectiveness, assuming the patient adheres to the medication, and decreases in reported adverse effects. These are the yet reported advantages of growth hormones compared to other treatment modalities available in the market currently.
The human growth hormone report highlights North America to be the largest regional market by 2031. Presence of key market participants as well as the FDA's commercialization of growth hormone are augmenting human growth hormone market development in the region.
Asia Pacific is likely to record a substantial rise in human growth hormone market share in the near future. India, China, and Australia are key countries boosting market statistics in Asia Pacific. Rise in number of people suffering from growth hormone insufficiency offers lucrative human growth hormone industry opportunities for companies operating in the region.
Merck KGaA, Pfizer Inc., Eli Lilly and Company, Novartis AG, Novo Nordisk A/S, Anhui Anke Biotechnology (Group) Co., Ltd, Biopartners GmbH, Ipsen S.A, GeneScience Pharmaceuticals Co., Ltd., and Roche Holdings, Inc. are some of the prominent companies operating in the global human growth hormone market.
Leading players are engaging in acquisitions and collaborations to expand their geographic footprint in the worldwide growth hormone therapy market. They are also making investments in R&D activities to develop advanced and customized devices for monitoring of treatment of human growth hormone disorders.
Prominent players have been profiled in the human growth hormone market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 2.8 Bn |
| Market Forecast Value in 2031 | US$ 3.9 Bn |
| Growth Rate (CAGR) | 3.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 2.8 Bn in 2022
It is likely to grow at a CAGR of 3.7% from 2023 to 2031
Evolution of clinical practice guidelines and advancements in recombinant human growth hormone treatment
The subcutaneous segment is likely to account for significant share during the forecast period
North America was the leading region in 2022
Merck KGaA, Pfizer Inc., Eli Lilly and Company, Novartis AG, Novo Nordisk A/S, Anhui Anke Biotechnology (Group) Co., Ltd, Biopartners GmbH, Ipsen S.A, GeneScience Pharmaceuticals Co., Ltd., and Roche Holdings, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Human Growth Hormone Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Growth Hormone Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
5.3. COVID-19 Pandemic Impact on Industry
6. Global Human Growth Hormone Market Analysis and Forecast, by Route of Administration
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Route of Administration, 2023–2031
6.3.1. Intravenous
6.3.2. Subcutaneous
6.3.3. Intramuscular
6.3.4. Oral
6.4. Market Attractiveness Analysis, by Route of Administration
7. Global Human Growth Hormone Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
7.3.1. Hospital Pharmacy
7.3.2. Online Pharmacy
7.3.3. Retail Pharmacy
7.3.4. Clinics
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Human Growth Hormone Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2023–2031
8.3.1. Growth Hormone Deficiency
8.3.2. Turner Syndrome
8.3.3. Idiopathic Short Stature
8.3.4. Prader-Willi Syndrome
8.3.5. Other Indications
8.4. Market Attractiveness Analysis, by Indication
9. Global Human Growth Hormone Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Human Growth Hormone Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Route of Administration, 2023–2031
10.3.1. Intravenous
10.3.2. Subcutaneous
10.3.3. Intramuscular
10.3.4. Oral
10.4. Market Value Forecast, by Distribution Channel, 2023–2031
10.4.1. Hospital Pharmacy
10.4.2. Online Pharmacy
10.4.3. Retail Pharmacy
10.4.4. Clinics
10.5. Market Value Forecast, by Indication, 2023–2031
10.5.1. Growth Hormone Deficiency
10.5.2. Turner Syndrome
10.5.3. Idiopathic Short Stature
10.5.4. Prader-Willi Syndrome
10.5.5. Other Indications
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Route of Administration
10.7.2. By Distribution Channel
10.7.3. By Indication
10.7.4. By Country
11. Europe Human Growth Hormone Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Route of Administration, 2023–2031
11.3.1. Intravenous
11.3.2. Subcutaneous
11.3.3. Intramuscular
11.3.4. Oral
11.4. Market Value Forecast, by Distribution Channel, 2023–2031
11.4.1. Hospital Pharmacy
11.4.2. Online Pharmacy
11.4.3. Retail Pharmacy
11.4.4. Clinics
11.5. Market Value Forecast, by Indication, 2023–2031
11.5.1. Growth Hormone Deficiency
11.5.2. Turner Syndrome
11.5.3. Idiopathic Short Stature
11.5.4. Prader-Willi Syndrome
11.5.5. Other Indications
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Route of Administration
11.7.2. By Distribution Channel
11.7.3. By Indication
11.7.4. By Country/Sub-region
12. Asia Pacific Human Growth Hormone Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Route of Administration, 2023–2031
12.3.1. Intravenous
12.3.2. Subcutaneous
12.3.3. Intramuscular
12.3.4. Oral
12.4. Market Value Forecast, by Distribution Channel, 2023–2031
12.4.1. Hospital Pharmacy
12.4.2. Online Pharmacy
12.4.3. Retail Pharmacy
12.4.4. Clinics
12.5. Market Value Forecast, by Indication, 2023–2031
12.5.1. Growth Hormone Deficiency
12.5.2. Turner Syndrome
12.5.3. Idiopathic Short Stature
12.5.4. Prader-Willi Syndrome
12.5.5. Other Indications
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Route of Administration
12.7.2. By Distribution Channel
12.7.3. By Indication
12.7.4. By Country/Sub-region
13. Latin America Human Growth Hormone Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Route of Administration, 2023–2031
13.3.1. Intravenous
13.3.2. Subcutaneous
13.3.3. Intramuscular
13.3.4. Oral
13.4. Market Value Forecast, by Distribution Channel, 2023–2031
13.4.1. Hospital Pharmacy
13.4.2. Online Pharmacy
13.4.3. Retail Pharmacy
13.4.4. Clinics
13.5. Market Value Forecast, by Indication, 2023–2031
13.5.1. Growth Hormone Deficiency
13.5.2. Turner Syndrome
13.5.3. Idiopathic Short Stature
13.5.4. Prader-Willi Syndrome
13.5.5. Other Indications
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Route of Administration
13.7.2. By Distribution Channel
13.7.3. By Indication
13.7.4. By Country/Sub-region
14. Middle East & Africa Human Growth Hormone Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Route of Administration, 2023–2031
14.3.1. Intravenous
14.3.2. Subcutaneous
14.3.3. Intramuscular
14.3.4. Oral
14.4. Market Value Forecast, by Distribution Channel, 2023–2031
14.4.1. Hospital Pharmacy
14.4.2. Online Pharmacy
14.4.3. Retail Pharmacy
14.4.4. Clinics
14.5. Market Value Forecast, by Indication, 2023–2031
14.5.1. Growth Hormone Deficiency
14.5.2. Turner Syndrome
14.5.3. Idiopathic Short Stature
14.5.4. Prader-Willi Syndrome
14.5.5. Other Indications
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Route of Administration
14.7.2. By Distribution Channel
14.7.3. By Indication
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Merck KGaA
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Pfizer Inc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Novo Nordisk A/S
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ipsen SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Roche Holdings, Inc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Anhui Anke Biotechnology (Group) Co., Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Biopartners GmbH
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. GeneScience Pharmaceuticals Co., Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Novartis AG
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Human Growth Hormone Market Size (US$ Mn) Forecast, by Route of Administration, 2023–2031
Table 02: Global Human Growth Hormone Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 03: Global Human Growth Hormone Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 04: Global Human Growth Hormone Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 05: North America Human Growth Hormone Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 06: North America Human Growth Hormone Market Size (US$ Mn) Forecast, by Route of Administration, 2023–2031
Table 07: North America Human Growth Hormone Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 08: North America Human Growth Hormone Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 09: Europe Human Growth Hormone Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Human Growth Hormone Market Size (US$ Mn) Forecast, by Route of Administration, 2023–2031
Table 11: Europe Human Growth Hormone Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 12: Europe Human Growth Hormone Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 13: Asia Pacific Human Growth Hormone Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Human Growth Hormone Market Size (US$ Mn) Forecast, by Route of Administration, 2023–2031
Table 15: Asia Pacific Human Growth Hormone Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 16: Asia Pacific Human Growth Hormone Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 17: Latin America Human Growth Hormone Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin America Human Growth Hormone Market Size (US$ Mn) Forecast, by Route of Administration, 2023–2031
Table 19: Latin America Human Growth Hormone Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 20: Latin America Human Growth Hormone Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 21: Middle East & Africa Human Growth Hormone Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Human Growth Hormone Market Size (US$ Mn) Forecast, by Route of Administration, 2023–2031
Table 23: Middle East & Africa Human Growth Hormone Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 24: Middle East & Africa Human Growth Hormone Market Size (US$ Mn) Forecast, by Indication, 2023–2031
List of Figures
Figure 01: Global Human Growth Hormone Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Human Growth Hormone Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 03: Global Human Growth Hormone Market Value Share, by Route of Administration, 2022
Figure 04: Global Human Growth Hormone Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 05: Global Human Growth Hormone Market Value Share, by Distribution Channel, 2022
Figure 06: Global Human Growth Hormone Market Revenue (US$ Mn), by Indication, 2022
Figure 07: Global Human Growth Hormone Market Value Share, by Indication, 2022
Figure 08: Global Human Growth Hormone Market Value Share, by Region, 2022
Figure 09: Global Human Growth Hormone Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Human Growth Hormone Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 11: Global Human Growth Hormone Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 12: Global Human Growth Hormone Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 13: Global Human Growth Hormone Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 14: Global Human Growth Hormone Market Value Share Analysis, by Indication, 2022 and 2031
Figure 15: Global Human Growth Hormone Market Attractiveness Analysis, by Indication, 2023-2031
Figure 16: Global Human Growth Hormone Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Human Growth Hormone Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Human Growth Hormone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 19: North America Human Growth Hormone Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Human Growth Hormone Market Value Share Analysis, by Country, 2023 and 2031
Figure 21: North America Human Growth Hormone Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 22: North America Human Growth Hormone Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 23: North America Human Growth Hormone Market Value Share Analysis, by Indication, 2022 and 2031
Figure 24: North America Human Growth Hormone Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 25: North America Human Growth Hormone Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 26:North America Human Growth Hormone Market Attractiveness Analysis, by Indication, 2023–2031
Figure 27: Europe Human Growth Hormone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 28: Europe Human Growth Hormone Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Human Growth Hormone Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Human Growth Hormone Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 31: Europe Human Growth Hormone Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 32: Europe Human Growth Hormone Market Value Share Analysis, by Indication, 2022 and 2031
Figure 33: Europe Human Growth Hormone Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 34: Europe Human Growth Hormone Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 35: Europe Human Growth Hormone Market Attractiveness Analysis, by Indication, 2023–2031
Figure 36: Asia Pacific Human Growth Hormone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 37: Asia Pacific Human Growth Hormone Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Human Growth Hormone Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Human Growth Hormone Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 40: Asia Pacific Human Growth Hormone Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 41: Asia Pacific Human Growth Hormone Market Value Share Analysis, by Indication, 2022 and 2031
Figure 42: Asia Pacific Human Growth Hormone Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 43: Asia Pacific Human Growth Hormone Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 44: Asia Pacific Human Growth Hormone Market Attractiveness Analysis, by Indication, 2023–2031
Figure 45: Latin America Human Growth Hormone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 46: Latin America Human Growth Hormone Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Human Growth Hormone Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Human Growth Hormone Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 49: Latin America Human Growth Hormone Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 50: Latin America Human Growth Hormone Market Value Share Analysis, by Indication, 2022 and 2031
Figure 51: Latin America Human Growth Hormone Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 52: Latin America Human Growth Hormone Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 53: Latin America Human Growth Hormone Market Attractiveness Analysis, by Indication, 2023–2031
Figure 54: Middle East & Africa Human Growth Hormone Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 55: Middle East & Africa Human Growth Hormone Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Human Growth Hormone Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Human Growth Hormone Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 58: Middle East & Africa Human Growth Hormone Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 59: Middle East & Africa Human Growth Hormone Market Value Share Analysis, by Indication, 2022 and 2031
Figure 60: Middle East & Africa Human Growth Hormone Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 61: Middle East & Africa Human Growth Hormone Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 62: Middle East & Africa Human Growth Hormone Market Attractiveness Analysis, by Indication, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Human Growth Hormone Market
